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Abstract 26
Hepatitis E Virus (HEV) genome encodes three proteins including the ORF2 protein 27 that is the viral capsid protein. Recently, we developed an efficient HEV cell culture system 28 and demonstrated that this virus produces three different forms of its capsid protein: (i) the 29 ORF2i form (infectious/intracellular) which is the form associated with the infectious 30 particles, (ii) the ORF2g (glycosylated ORF2) and ORF2c (cleaved ORF2) forms that are 31 massively secreted glycoproteins not associated with infectious particles, but are the major 32 antigens present in HEV-infected patient sera. The ORF2 protein sequence contains three 33 highly conserved potential N-glycosylation sites (N1, N2 and N3). Although ORF2 protein is 34 the most characterized viral protein, its glycosylation status and the biological relevance of 35 this post-translational modification is still unclear. In the present study, we constructed and 36 extensively characterized a series of ORF2 mutants in which the three N-glycosylation sites 37 were mutated individually or in combination. We demonstrated that the ORF2g/c protein is 38 N-glycosylated on N1 and N3 sites but not on the N2 site. We showed that N-glycosylation of 39 ORF2 protein does not play any role in replication and assembly of infectious HEV particles. 40
We found that glycosylated ORF2g/c forms are very stable proteins which are targeted by 41 patient antibodies. During our study, we also demonstrated that the ORF2i protein is 42 translocated into the nucleus of infected cells. In conclusion, our study led to new insights 43 into the molecular mechanisms of ORF2 expression. 44 45 Introduction 59 Hepatitis E virus (HEV) is the most common cause of acute viral hepatitis worldwide. 60
This virus infects approximately 20 million people every year and is responsible for 3.4 61 million symptomatic cases and 70,000 deaths, mainly in regions of the world with low 62 sanitary conditions (1). Although HEV infection is usually asymptomatic and self-resolving, 63 severe forms in pregnant women (2) and chronic infections in immunocompromised patients 64
(3) have been described. In addition, HEV infection has been associated with a broad range of 65 extrahepatic manifestations, including renal and neurological manifestations (3). HEV strains 66 infecting humans have been classified into 4 main distinct genotypes (gt) belonging to a 67 single serotype. Gt1 and gt2 exclusively infect humans, are spread mainly through 68 contaminated drinking water and represent main causes of waterborne outbreaks of hepatitis 69 in developing countries. In contrast, gt3 and gt4 are zoonotic and mainly infect mammals. 70
Their main reservoirs are pigs and game (4). The major transmission routes of gt3 and gt4 are 71 direct contact with infected animals, consumption of contaminated food and transfusion of 72 blood products. In industrialized countries, the most common genotype causing HEV 73 infection is gt3. Importantly, due to the evolution toward chronicity in immunocompromised 74 infected patients, HEV transmission through blood transfusion, resistance of some infected 75 patients to ribavirin and complications in patients with preexisting liver disease, HEV 76 infection is now considered as an emerging problem in industrialized countries (5). 77 HEV is a quasi-enveloped virus (6-8) containing a linear, single-stranded, positive-78 sense RNA genome that contains three open reading frames (ORFs), namely, ORF1, ORF2 79 and ORF3 (9). ORF1 encodes a non-structural polyprotein (ORF1 protein) that is essential for 80 viral replication (10). It includes methyltransferase (Met), papain-like cysteine protease 81 (PCP), RNA helicase (Hel) and RNA-dependent RNA polymerase (RdRp) domains (reviewed 82 in (1)). ORF2 encodes the ORF2 viral capsid protein and ORF3 encodes a small 83 multifunctional phosphoprotein that is involved in virion morphogenesis and egress (reviewed 84 in (11)). 85
The ORF2 protein sequence contains 660 amino acids, a signal peptide sequence at its 86 N-terminus and three highly conserved potential N-glycosylation sites represented by the 87 sequon Asn-X-Ser/Thr (N-X-S/T) (12-14). The ORF2 protein has been largely studied and is 88 the most characterized HEV viral protein. However, whether using various heterologous 89 expression systems (14-17) or infectious systems (8, 13), the glycosylation status of ORF2 90 and the biological relevance of this post-translational modification was still controversial until 91 recently. Indeed, by combining the highly replicative and cell culture-selected gt3 p6 strain 92 (18) and a highly transfectable subclone of PLC/PRF/5 cells (PLC3 cells), we recently 93 developed an efficient HEV cell culture system and demonstrated for the first time that, 94 during its lifecycle, HEV produces 3 forms of the ORF2 capsid protein ( Figure 1A) : 95 infectious/intracellular ORF2 (ORF2i), glycosylated ORF2 (ORF2g), and cleaved ORF2 96 (ORF2c) (19). We identified the precise sequence of the ORF2i and ORF2g proteins. The 97
ORF2i protein is the form that is associated with infectious particles. The ORF2i protein is 98 not glycosylated and is likely not translocated into the endoplasmic reticulum (ER) lumen and 99 stays in the cytosolic compartment. In contrast, ORF2g and ORF2c proteins are secreted in 100 large amounts in cell culture and infected patient sera, sialylated, N-and O-glycosylated but 101 are not associated with infectious virions. The identification of these 3 forms of ORF2 led us 102 to suggest the existence of two production pathways for the HEV capsid protein: (i) a major 103 non-productive pathway in which ORF2 proteins are addressed to the secretion route where 104 they are glycosylated, maturated and quickly secreted. (ii) a productive pathway in which 105 cytosolic ORF2 proteins are delivered to the virion assembly sites (19). Importantly, ORF2g 106 and ORF2c are the most abundant antigens detected in sera from patients (19) . Whether 107 ORF2g and ORF2c proteins play a specific role in the HEV lifecycle or have functions in host 108 immune response needs to be elucidated. 109
In the present study, we took advantage of our HEV cell culture system, in which 110 ORF2 proteins are robustly expressed, to analyze the significance of N-glycosylation of the 111 ORF2 protein in the HEV lifecycle. Using site-directed mutagenesis of the full-length 112 infectious p6 clone, we constructed a series of ORF2 mutants in which the three potential N-113 glycosylation sites ( 137 NLS, N1; 310 NLT, N2; 562 NTT, N3) were mutated individually or in 114 combination. We performed an extensive characterization of these mutants by analyzing their 115 subcellular localization, expression, oligomerization, stability and recognition by antibodies. 116
We also studied the impact of mutations on assembly, density and infectivity of HEV 117 particles. In addition to analyzing the glycosylation status of ORF2 protein and the biological 118 relevance of this modification in the HEV life cycle, we obtained new insights into the 119 molecular mechanisms of ORF2 expression. 120 121
Generation of HEV p6 genomes expressing mutations of ORF2 N-glycosylation sites. 123
The ORF2 protein sequence displays a signal peptide sequence at its N-terminus and 124 three potential N-glycosylation sites, 137 NLS (N1), 310 NLT (N2), and 562 NTT (N3) ( Figure  125   1B) . Previously, we demonstrated that the first amino acids (aa) of ORF2i and ORF2g 126 proteins are Leu 14 and Ser 34 , respectively (19). Here, by using the same mass spectrometry 127 approach, we found that the first aa of ORF2c protein corresponds to Ser 102 (Figure 1B Using site-directed mutagenesis of the full-length infectious p6 clone, we constructed 130 a series of ORF2 mutants in which N1, N2 and N3 sites were mutated individually (N1, N2 131 and N3 mutants) or in combination (Gly(-) and Gly(+) mutants) ( Figure 1B) . For each single 132 mutant, three substitutions of the N-X-S/T sequon were generated: N-to-A (S1), S/T-to-A 133 (S2) and S-to-T/T-to-S (S3). S1 and S2 substitutions were made to prevent N-glycosylation 134 (Red), whereas S3 substitution does not affect N-glycan addition (Green). A fourth 135 substitution (S4) was done for the N2 site in which a Proline (P) residue downstream of the 136 sequon was replaced by an Alanine ( 313 P-to-A). In Gly(-) and Gly(+) mutants, two 137 combinations of mutations affecting (N1S2/N3S1) or not (N1S3/N3S3) the N-glycan addition 138 on N1 and N3 glycosylation sites were introduced, respectively ( Figure 1B) . Mutants 139 expressing mutations that theoritically abolish N-glycosylation are in Red. Mutants 140 expressing mutations that theoritically do not disturb or improve N-glycosylation (N2S4) are 141 in Green. Capped RNAs transcripts of wild type (wt) and mutant (mut) HEV genomes were 142 generated and delivered into PLC3 cells by electroporation. We first evaluated the expression and subcellular localization of mutant ORF2 148 proteins by indirect immunofluorescence. PLC3 cells electroporated with wild type and 149 mutants of HEV-p6 RNAs (wt and mt PLC3/HEV-p6 cells) were fixed at 3 days post-150 electroporation (d.p.e.) and processed for ORF2 staining. For all constructs, over 90% of cells 151 were ORF2-positive indicating that robust replication and expression of viral genome 152 occurred in wt and mt PLC3/HEV-p6 cells (data not shown). As shown in Figure 3A , the wt 153 ORF2 protein displayed mostly a cytoplasmic localization but also a nuclear localization, as 154 recently described (20). Although mutant ORF2 proteins were globally expressed as the wt 155 ORF2 protein, N1 mutants showed a slightly more perinuclear localization ( Figure 3A) , N2 156 mutants showed a concentrated staining in a spot close to the nucleus ( Figure 3B) whereas 157 N3 mutants showed a subcellular localization similar to that of wt ORF2 proteins ( Figure  158 To characterize the impact of N-glycosylation site mutations on the ORF2 protein 169 profile and oligomerization, ORF2 protein expression in supernatants and lysates of wt and 170 mt PLC3/HEV-p6 cells was characterized by western blotting (WB). As shown in Figure 4A , 171 a single band was detected in all cell lysates, which corresponds to ORF2i as previously described (19), immunofluorescence stainings observed in Figure 3 thus corresponded mainly 173 to the subcellular localization of ORF2i proteins. We observed no shift of migration between 174 wt and mutant proteins, even for the mutants carrying mutations that inhibit N-glycosylation. 175
These results confirm that the ORF2i protein is not N-glycosylated, as previously described 176 (19) . In the supernatants of transfected cells, the three forms of the ORF2 protein (ORF2g, 177
ORF2i and ORF2c) were identified ( Figure 4B) . Interestingly, we observed a shift of 178 migration of ORF2g and ORF2c proteins for the mutants that inhibit N-glycosylation on N1 179 or N3 sites or both (N1S1, N1S2, N3S1, N3S2 and Gly(-)), as compared to wt protein ( Figure  180 4B and Figure 4D ). In contrast, no shift of migration was observed for proteins carrying 181 mutations that do not affect glycosylation of N1 and N3 sites (N1S3, N3S3 and Gly(+)). 182
These results indicate that both N1 and N3 sites of the ORF2 protein are likely occupied by 183 N-glycans. Analyses of N2S1, N2S2 and N2S3 mutants showed that their ORF2g and ORF2c 184 proteins behaved similarly whatever the introduced mutation (affecting or not glycosylation) 185
prevented us from drawing conclusions about the N-glycosylation status of the N2 site. 186 However, since it has been demonstrated that a proline residue right downstream of the N-X-187 S/T sequon constitutes an unfavorable context for N-linked glycan modification (21), we 188 generated an additional mutant of the N2 site in which we replaced the Proline 313 by an 189
Alanine residue (N2S4) (Figure 1) . Interestingly, N2S4 ORF2g and ORF2c proteins 190 displayed a higher apparent molecular weight than the wt forms ( Figure 4B) , indicating that 191 the N2S4 mutation likely leads to the addition of a supplementary N-glycan on ORF2 192 proteins. Together, these results indicate that the N2 site is likely not N-glycosylated in the 193 context of wt ORF2 proteins. 194
To further characterize which site of ORF2 protein is truly N-glycosylated, 195 representative mutants were selected (N1S1, N2S1, N2S4, N3S1 and Gly(-)) and further 196 characterized. Supernatants and lysates of wt and mt PLC3/HEV-p6 cells were denatured and 197 digested with Peptide-N-Glycosidase F (PNGaseF), a glycosidase that cleaves between the 198 innermost N-acetyl glucosamine and asparagine residues of N-glycoproteins. The proteins 199 were resolved by SDS-PAGE and ORF2 proteins were detected by WB. As shown in Figure  200 4E, wt and mt ORF2i proteins expressed from cell lysates were resistant to glycosidase 201 digestion, strengthening the fact that ORF2i protein in cell lysates is not N-glycosylated. In 202 contrast, we observed a shift of migration between untreated (-) and treated (+) condition for 203 the secreted wt and mutants N1S1, N2S1, N2S4 and N3S1 ( Figure 4F) . Importantly, no shift 204 was observed for the Gly(-) double mutant carrying mutations that inhibit N-glycosylation on 205 N1 and N3 sites, confirming that the N2 site is not occupied by N-glycans. In addition for the 206 N2S4 mutant, we observed a higher migration shift between untreated (-) and treated (+) 207
ORF2g and ORF2c proteins, as compared to wt (Figure 4F) . 208
To further confirm which sites of N-glycosylation are occupied by glycans on ORF2 209 protein, we next performed mass spectrometry analyses. ORF2g/ORF2c proteins 210 immunoprecipitated with an anti-ORF2 antibody (4B2) were treated or left untreated with 211
PNGaseF. Proteins were resolved by SDS-PAGE and Colloïdal blue-stained bands 212 corresponding to ORF2g and ORF2c proteins in WB (data not shown) were digested in-gel 213 with trypsin (Tryp) or AspN and then analyzed by nano scale liquid chromatography coupled 214 to tandem mass spectrometry. Detected peptides were compared to the theorical peptide 215 sequences of non N-glycosylated or PNGaseF-deglycosylated ORF2 protein digested with 216 Tryp or AspN. As shown in Table 1 , when ORF2g/c proteins were not treated with PNGaseF, 217 no peptides covering N1 and N3 sites were detected after digestion with Tryp or AspN. In 218 contrast, upon treatment with PNGaseF, peptides covering N1 and N3 sites were detected 219 after digestion with Tryp or AspN, indicating that N1 and N3 sites are most likely occupied 220 by N-glycans (modifying the mass of peptides covering them and therefore their detection in 221 the absence of PNGaseF treatment). Interestingly, peptides covering the N2 site were detected 222 in both treated and untreated samples digested with Tryp or AspN, indicating that the 223 probability that the site N2 is occupied by N-glycans is very low ( Table 1) . 224
Taken together, our results demonstrate that the ORF2 protein is N-glycosylated on 225 N1 ( 137 NLS) and N3 ( 562 NTT) sites but not on the N2 ( 310 NLT) site. 226 227
Impact of mutations of ORF2 N-glycosylation sites on the oligomerization and stability 228 of the ORF2 capsid protein 229
The impact of mutations of ORF2 N-glycosylation sites on the oligomerization of the 230 ORF2 capsid protein was next assessed by analyzing supernatants and lysates of wt and mt 231 PLC3/HEV-p6 cells prepared in non-reducing conditions. Oligomers of ORF2i and 232 glycosylated ORF2 proteins were clearly detected ( Figure 4C and Figure 4D , asterisks). 233
Taking into account the differences in individual protein expression levels (Figure 4A) , no 234 significant differences in the oligomerization levels of ORF2 proteins was observed between 235 wt and mutants. 236
We next analyzed the significance of ORF2 N-glycosylation for protein stability. For 237 this purpose, supernatants of wt and mt PLC3/HEV-p6 cells were kept during 0, 10 and 20 238 days at 37°C and analyzed by WB ( Figure 4G) . Surprisingly, even after 20 days of 239 incubation, ORF2g and ORF2c proteins were still readily detected, indicating that these 240 proteins are very stable and poorly degraded in culture medium. Quantification by 241 densitometry of ORF2 levels in wt and N2S4 supernatants, showed that only 30-35% of 242 proteins were degraded after 20 days. In contrast, 60% of Gly(-) and Gly(+) proteins were 243 degraded after 20 days, indicating that these mutants are less stable in culture medium but in a 244 glycosylation-independent manner. 245
246
To determine the impact of mutations of N-glycosylation sites on the anti-ORF2 248 antibody recognition, ORF2 proteins in cell lysates and supernatants of wt and mt 249 PLC3/HEV-p6 cells were immunoprecipitated with either a linear (1E6) or two 250 conformational (4B2 and 2E2, (22)) anti-ORF2 MAbs, and analyzed by WB (Figure 5) . 251
Although some detection differences were observed for several mutants, likely reflecting 252 some differences in individual protein expression levels (Figure 5A , input), mutant ORF2i 253 proteins were recognized by the three antibodies ( Figure 5A) . The supernatants were 254 standardized according to the ORF2i expression levels and then immunoprecipitated with 255 1E6, 4B2 and 2E2 MAbs. As shown in Figure 5B , ORF2g and ORF2c proteins were equally 256 immunoprecipitated by the three antibodies. We also quantified levels of secreted ORF2 257 proteins with the Wantaï HEV-antigen ELISA Plus assay that has been recently marketed for 258 HEV diagnosis and that works with monoclonal and polyclonal antibodies (Wantaï Biological 259 Pharmacy Enterprise). As shown in Figure 5C , no significant differences were observed in 260 protein detection between wt and mt ORF2 proteins. 261
We next sought to determine whether mutations of N-glycosylation sites affect 262 recognition by patient antibodies. For this purpose, we used a serum from a patient who has 263 cleared his HEV infection (serum S30) and a serum from a non-infected patient (serum N6). 264 Sera were incubated with protein A-agarose beads and then with ORF2g/ORF2c proteins or 265 PBS (CTL) (Figure 5D ). ORF2g/ORF2c proteins were isolated on iodixanol cushions, as 266 previously described (19). ORF2g and ORF2c proteins were specifically immunoprecipitated 267 by immunoglobulins raised in the S30 patient serum whereas no proteins were precipitated by 268 the N6 negative serum. As shown in Figure 5E that, in addition to its cytoplasmic localization, the ORF2 protein might also translocate into 281 the nucleus of infected cells, we next further characterized this process by WB and 282 immunofluorescence. We prepared cytoplasmic and nuclear extracts from wt and mt 283 PLC3/HEV-p6 cells. Proteins were resolved by SDS-PAGE and the ORF2 protein was 284 detected by WB. Cytoplasmic-specific anti-tubulin and nuclear envelope-specific anti-Lamin-285 B1 antibodies were used to control the quality of extractions. As expected, the ORF2i protein 286 was detected in cytoplasmic extracts of wt and mt PLC3/HEV-p6 cells (Figure 6A) . 287
Interestingly, wt and mutant ORF2 proteins were also detected in nuclear extracts ( Figure  288 6B). We named this protein ORF2ni for nuclear ORF2i. Among mutants of N-glycosylation, 289 some differences in the ORF2ni detection were observed (Figure 6B) . N1S3, N2S2, N2S3, 290
Gly(-) and Gly(+) mutants showed reduced ORF2ni amounts whereas nuclear translocation 291 was likely not affected for the other mutants, as compared to the wt protein. In order to 292 quantify the effect of mutations of N-glycosylation sites on nuclear translocation, nuclear 293 fluorescence intensity of ORF2 protein was measured on 50 cells for each mutant with the 294 ImageJ software. As shown in Figure 6C , a significant reduction of nuclear translocation was 295 observed for all mutants excepted for the N2S1 mutant and the three mutants of the N3 site. 296
However, we did not observe any correlation between the status of N-glycosylation of ORF2 297 and its nuclear localization. 298
Altogether, our results demonstrate that, during HEV lifecycle, the ORF2 capsid 299 protein is translocated into the nucleus of infected cells. This nuclear localization is not 300 closely related to the ORF2 protein N-glycosylation. 301 302
Impact of mutations of ORF2 protein N-glycosylation sites on viral assembly and 303
infectivity 304
Next, we analyzed the impact of mutations of ORF2 protein N-glycosylation sites on 305 viral RNA production and infectivity. Supernatants of wt and mt PLC3/HEV-p6 cells were 306 collected at 2, 6 and 10 d.p.e. and then processed for RNA level quantification by RT-qPCR 307 ( Figure 7A ) and determination of extracellular infectious titers (Figure 7B) . It has to be 308 noted that, in order to specifically quantify capsid-protected RNA genomes, extractions and 309 quantifications of extracellular RNA were performed after treatment of supernatants with 310
RNase. Quantification of extracellular RNA genomes and calculation of fold increase 311 between 2, 6 and 10 d.p.e., which are in line with HEV RNA replication and secretion of 312 capsid-protected RNA genomes, showed that mutants of the N2 site led to a reduction of 313 RNA replication and/or secretion of capsid-protected RNA genomes (Figure 7A) , whereas 314 extracellular RNA levels of N1, N3 and double mutants were similar to wt genome. To 315 determine viral infectivity, Huh-7.5 cells were infected with serial dilutions of supernatants 316 and processed for ORF2 staining at 3 d.p.i. Viral titers were determined by quantifying focus 317 forming units (FFU/mL) ( Figure 7B) . As expected, supernatants of N2 mutants were not 318 infectious. Supernatants of N1 and double mutants displayed reduced infectivity. Although 319 the N3S1 mutant was slightly less infectious, other mutants of the N3 site displayed infectious 320 titers similar to wt strain. These results indicate that mutations of the N1 site inhibit 321 infectivity of viral particles whereas mutations of the N3 site have no major impact on the 322 biogenesis of infectious HEV particles. 323
In order to precisely define the impact of mutations on HEV RNA replication, we 324 quantified the levels of intracellular viral RNA genomes. Although several significant 325 differences were observed among mutants, intracellular RNA replication was globally not 326 affected by the mutations of ORF2 protein N-glycosylation sites (Figure 7C) . Finally, we 327 determined the infectivity of intracellular particles produced in wt and mt PLC3/HEV-p6 cells 328 ( Figure 7D) . N2S3, N2S4 and Gly(-) PLC3/HEV-p6 cells did not produce any infectious 329 particles, indicating that these mutations are lethal for assembly of infectious HEV particles. 330 N1 mutants, N2S1, N2S2 and Gly(+) mutants displayed highly reduced intracellular titers, 331
indicating that these mutations affect assembly and infectivity of HEV particles. As for 332 extracellular titers, the N3S1 mutant was slightly less infectious whereas N3S2 and N3S3 333 mutants displayed intracellular titers similar to wt strain. 334
Taken together, our results show that (i) mutations of N1 glycosylation site inhibit 335 infectivity of HEV particles, (ii) mutations of N2 glycosylation site inhibit assembly of HEV 336 particles and (iii) mutations of N3 glycosylation site have little or no effect on assembly of 337 infectious HEV particles. Importantly, whatever the introduced mutation within the same site 338 (affecting or not N-glycosylation) the same phenotype was observed indicating that N-339 glycosylation of ORF2 protein does not play any role in assembly of infectious HEV 340 particles. 341 342
Impact of mutations of ORF2 protein N-glycosylation sites on particle density 343
To further characterize our mutants, we produced large amounts of infectious 344 supernatants by culturing wt and mt PLC3/HEV-p6 cells during 12 days. Supernatants were 345 pooled, concentrated, and fractionated on an iodixanol gradient. ORF2 protein expression, 346 density and RNA levels were determined for each fraction (Figure 8 A-G) . As previously, 347 only some representative mutants were analyzed (N1S1, N2S1, N2S4, N3S1, Gly(-) and 348 Gly(+)). ORF2g and ORF2c proteins were highly enriched in fractions 4 and 5 whereas the 349
ORF2i protein was mainly observed in fraction 5 or 6 of wt or mutants that assembled 350 particles (N1S1, N3S1, Gly(-) and Gly(+)). In accordance with our previous results ( Figure  351   7) , N2S1 and N2S4 mutants displayed no ORF2i and no extracellular RNAs confirming that 352 the mutations of N2 glycosylation site inhibit assembly of HEV particles. As described 353 previously (19), only one major peak of RNA was detected in fraction 6, with a density of 354 1.11 g/mL, for wt and N3S1 gradients. In contrast, N1S1, Gly(-) and Gly(+) displayed a RNA 355 peak in fraction 4 or 5 with a density of 1.10 g/mL, indicating that non-infectious mutants 356 have a slightly lower density, as compared to infectious particles. 357
358
Discussion 359 We recently demonstrated that during its infectious cycle, HEV produces three 360 different forms of its ORF2 capsid protein (19) The ORF2 protein has been largely studied and is the most characterized HEV viral 376 protein. Notably, its glycosylation status has been analyzed by several laboratories but no 377 clear evidence was depicted about the biological relevance of this post-translational 378 modification in the HEV life cycle. As early as 1996, by using SV40-based expression 379 vectors in COS-1 cells, Jameel and collaborators described the gt1 ORF2 protein as an 88kDa 380 glycoprotein which is expressed intracellularly as well as on cell surface and has the potential 381 to form non covalent homodimers (15). Later on, using the same expression system, they 382 demonstrated that Asn-310 (N2 site) is the major but not the only site of N-glycan addition 383 glycosylation sites of the gt1 Sar55 infectious full-lenght genome (13). They observed no 385 difference in electrophoretic migration rates of wildtype glycosylated and mutant 386 nonglycosylated ORF2 proteins in cell lysates, suggesting that ORF2 protein accumulating 387 within transfected S10-3 cells is not glycosylated. They also demonstrated that mutation of 388 the first 2 glycosylation sites prevented virion assembly and mutation of the third site did not 389 affect particle formation and RNA encapsidation but the particles were not infectious. 390
However, conservative mutations that did not affect glycosylation also prevented infection, 391 indicating that mutations of N-glycosylation sites were lethal because they perturbed protein 392 structure rather than because they eliminated glycosylation (13). In our study, by using site-393 directed mutagenesis of the three N-glycosylation sites, PNGaseF treatment and mass 394 spectrometry analyses of ORF2 protein expressed from our efficient gt3 p6 full-length strain-395 based HEV cell culture system, we robustly demonstrated that the ORF2 protein is N-396 glycosylated on N1 ( 137 NLS) and N3 ( 562 NTT) sites but not on the N2 ( 310 NLT) site. The 397 absence of N-glycan addition on N2 site is likely due to the presence of a Proline 313 residue 398 immediately downstream of the 310 NLT sequon, which has a deleterious effect on N-glycan 399 addition (24). In accordance with this claim, we showed that the Proline 313 to Alanine 313 400 substitution (N2S4 mutant) induced additional ORF2 N-glycosylation. It has to be noted that 401 alignment of 293 sequences from genotype 1 to genotype 4 HEV strains showed that the 402 Proline 313 is highly conserved (25), suggesting that the absence of N-glycans on ORF2 N2 site 403 is likely a conserved process among HEV genotypes. We have been able to robustly analyze 404 the glycosylation status of ORF2 thanks to the high expression levels of this protein in our 405 replicative system. It would be now also interesting to develop a similar cell culture system 406 for the gt1 HEV in order to robustly analyzed the glycosylation status of the gt1 ORF2 407 protein. 408 potential N-glycosylation sites were mutated individually or in combination. Whatever the 410 introduced mutations, we observed no significant differences in expression, secretion, 411 oligomerization, stability and recognition by antibodies of the secreted ORF2g and ORF2c 412 proteins. However, we showed that ORF2g and ORF2c proteins were very stable and poorly 413 degraded when kept in culture medium at 37°C, which is consistent with previous 414 observations showing that ORF2 protein remained detectable for more than 100 days after 415 HEV RNA clearance in ribavirin-treated patients with chronic HEV infection (23). 416 Importantly, we showed that ORF2g and ORF2c proteins were the main antigens recognized 417 by antibodies from a patient who had cleared his HEV infection (serum S30), indicating that 418 these glycosylated ORF2 forms are the main targets of the humoral response during HEV 419 infection. 420
The level of ORF2i protein expression and its recognition by MAbs were not affected 421 by mutations of N-glycosylation sites, which is in line with the fact that this protein is not 422 glycosylated. However, during our study, we demonstrated that intracellular ORF2 proteins 423 displayed both cytoplasmic and nuclear localization, as recently observed by 424 immunohistochemistry of liver biopsy from patients with hepatitis E (20). By performing 425 differential extractions and detection by western blotting, we demonstrated that the ORF2i 426 protein localized in the nuclear fraction of HEV producing cells. We named this fraction of 427
ORF2i, ORF2ni for nuclear ORF2i protein. Characterization of N-glycosylation mutants 428 showed that nuclear localization of ORF2ni is not closely related to the ORF2 protein N-429 glycosylation. Altogether, our results demonstrate that, during HEV life cycle, the ORF2 430 capsid protein is translocated into the nucleus of infected cells to presumably control certain 431 cellular functions to promote viral replication and/or alter the antiviral response of the 432 infected cell. Further studies are now necessary to decipher the mechanisms and significance 433 of ORF2 nuclear translocation in the HEV life cycle. 434
We analyzed the impact of mutations of ORF2 protein N-glycosylation sites on viral 435 RNA production and particle infectivity. None of the mutations had an effect on viral 436 replication. On the other hand, mutations of N1 glycosylation site inhibited infectivity of 437 HEV particles, mutations of N2 glycosylation site abolished assembly of HEV particles and 438 mutations of N3 glycosylation site had little or no effect on assembly of infectious HEV 439 particles. Importantly, as observed by Graff et al. (13) , whatever the introduced mutation, 440 affecting or not N-glycosylation, the same effects were observed, indicating that N-441 glycosylation of ORF2 protein does not play any role in assembly of infectious HEV 442 particles. Mutations likely induce modifications in ORF2i protein domains involved in 443 particle assembly. Interestingly, we observed that non-infectious particles were characterized 444 by a slightly lower density, as compared to infectious particles, which might reflect subtle 445 differences in ORF2 assembly leading to non-infectious particles. It has been suggested that 446 cytoplasmic localization of the ORF2 protein would depend on its ability to be 447 retrotranslocated from the ER by a glycosylation-dependent process (26). In that case, a non-448 glycosylated form of ORF2, such as our Gly(-) mutant, will not generate any cytoplasmic 449
ORF2i protein. However, the Gly(-) mutant produced ORF2i protein levels similar to that of 450 the wt ORF2, indicating that ORF2i proteins are likely not generated from a glycosylation-451 dependent retrotranslocation process. 452
Since the ORF2g/c proteins might interfere with the capacity of HEV virions to infect 453 target cells (19), we also performed inhibition assays of HEV infection in the presence of 454 mutant ORF2g/c proteins. However, we could not make any correlation between 455 glycosylation status and inhibition levels (data not shown). 
